OBJECTIVE: To determine the visual acuity outcomeat age 10 years for children younger than 7 years when enrolled in a treatment trial for moderate amblyopia. METHODS: In a multicenter clinical trial, 419 children with amblyopia (visual acuity, 20/40-20/100) were randomized to patching or atropine eyedrops for 6 months. Two years after enrollment, a subgroup of 188 children entered long-term follow-up. Treatment after 6 months was at the discretion of the investigator; 89% of children were treated. MAIN OUTCOME MEASURE: Visual acuity at age 10 years with the electronic Early Treatment Diabetic Retinopathy Study test. APPLICATION TO CLINICAL PRACTICE: Patching and atropine eyedrops produce comparable improvement in visual acuity that is maintained through age 10 years. RESULTS: The mean amblyopic eye acuity, measured in 169 patients, at age 10 years was 0.17 logMAR (logarithm of the minimum angle of resolution) (approximately 20/32), and 46% of amblyopic eyes had an acuity of 20/25 or better. Age younger than 5 years at entry into the randomized trial was associated with a better visual acuity outcome (P < .001). Mean amblyopic and sound eye visual acuities at age 10 years were similar in the original treatment groups (P = .56 and P = .80, respectively). CONCLUSIONS: At age 10 years, the improvement of the amblyopic eye is maintained, although residual amblyopia is common after treatment initiated at age 3 years to younger than 7 years. The outcome is similar regardless of initial treatment with atropine or patching.
RCT Entities:
OBJECTIVE: To determine the visual acuity outcome at age 10 years for children younger than 7 years when enrolled in a treatment trial for moderate amblyopia. METHODS: In a multicenter clinical trial, 419 children with amblyopia (visual acuity, 20/40-20/100) were randomized to patching or atropine eyedrops for 6 months. Two years after enrollment, a subgroup of 188 children entered long-term follow-up. Treatment after 6 months was at the discretion of the investigator; 89% of children were treated. MAIN OUTCOME MEASURE: Visual acuity at age 10 years with the electronic Early Treatment Diabetic Retinopathy Study test. APPLICATION TO CLINICAL PRACTICE: Patching and atropine eyedrops produce comparable improvement in visual acuity that is maintained through age 10 years. RESULTS: The mean amblyopic eye acuity, measured in 169 patients, at age 10 years was 0.17 logMAR (logarithm of the minimum angle of resolution) (approximately 20/32), and 46% of amblyopic eyes had an acuity of 20/25 or better. Age younger than 5 years at entry into the randomized trial was associated with a better visual acuity outcome (P < .001). Mean amblyopic and sound eye visual acuities at age 10 years were similar in the original treatment groups (P = .56 and P = .80, respectively). CONCLUSIONS: At age 10 years, the improvement of the amblyopic eye is maintained, although residual amblyopia is common after treatment initiated at age 3 years to younger than 7 years. The outcome is similar regardless of initial treatment with atropine or patching.
Authors: J M Holmes; R W Beck; M X Repka; D A Leske; R T Kraker; R C Blair; P S Moke; E E Birch; R A Saunders; R W Hertle; G E Quinn; K A Simons; J M Miller Journal: Arch Ophthalmol Date: 2001-09
Authors: Jonathan M Holmes; Roy W Beck; Raymond T Kraker; William F Astle; Eileen E Birch; Stephen R Cole; Susan A Cotter; Sean Donahue; Donald F Everett; Richard W Hertle; Ronald V Keech; Evelyn Paysse; Graham F Quinn; Michael X Repka; Mitchell M Scheiman Journal: J AAPOS Date: 2004-10 Impact factor: 1.220
Authors: Roy W Beck; Pamela S Moke; Andrew H Turpin; Frederick L Ferris; John Paul SanGiovanni; Chris A Johnson; Eileen E Birch; Danielle L Chandler; Terry A Cox; R Clifford Blair; Raymond T Kraker Journal: Am J Ophthalmol Date: 2003-02 Impact factor: 5.258
Authors: David K Wallace; Elizabeth L Lazar; Michael X Repka; Jonathan M Holmes; Raymond T Kraker; Darren L Hoover; Katherine K Weise; Amy L Waters; Melissa L Rice; Robert J Peters Journal: J AAPOS Date: 2015-02 Impact factor: 1.220
Authors: Christina Gambacorta; Mor Nahum; Indu Vedamurthy; Jessica Bayliss; Josh Jordan; Daphne Bavelier; Dennis M Levi Journal: Vision Res Date: 2018-05-12 Impact factor: 1.886
Authors: Jingyun Wang; Daniel E Neely; Jay Galli; Joshua Schliesser; April Graves; Tina G Damarjian; Jessica Kovarik; James Bowsher; Heather A Smith; Dana Donaldson; Kathryn M Haider; Gavin J Roberts; Derek T Sprunger; David A Plager Journal: J AAPOS Date: 2016-07-12 Impact factor: 1.220
Authors: David S Friedman; Michael X Repka; Joanne Katz; Lydia Giordano; Josephine Ibironke; Patricia Hawse; James M Tielsch Journal: Ophthalmology Date: 2009-09-16 Impact factor: 12.079